The CEO transition is routine and founder remains as Chair, so no immediate trading catalyst. Monitor any strategic updates from new CEO in upcoming quarters; the share issuance authorization may be used for future financing or acquisitions.
ARGX drugs
ARGX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $787.31entry
- T+1 · 6mo ago 0.00%α −0.83% · $787.31
- T+5 · 6mo ago +1.95%α +0.45% · $802.70
- T+20 · 6mo ago +3.28%α +0.14% · $813.14
- T+60 · 4mo ago +5.52%α +1.69% · $830.79
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
argenx announced results of its Annual General Meeting and the appointment of Karen Massey as CEO, succeeding founder Tim Van Hauwermeiren who becomes Chair. Shareholders approved all agenda items, including a 10% share issuance authorization. The leadership transition is orderly and the founder remains involved, limiting disruption risk.
Key Facts
- Karen Massey appointed CEO effective immediately, succeeding founder Tim Van Hauwermeiren.
- Tim Van Hauwermeiren appointed Chairperson of the Board.
- All agenda items approved at AGM, including 2025 remuneration report and annual accounts.
- Authorization to issue up to 10% of outstanding shares for 18 months, with pre-emptive rights exclusion possible.
- 90.9% of share capital represented at the meeting.
Financial Impact
No direct financial impact disclosed. Share issuance authorization could lead to dilution up to 10%.
Risk Factors
- Execution risk under new CEO if strategic direction changes materially.
- Potential dilution if share issuance authorization is utilized.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-056296 |
| Document: tm2613815d1_6k.htm | 0001104659-26-056296 |
| Document: 0001104659-26-056296-index-headers.html | 0001104659-26-056296 |
| Document: 0001104659-26-056296-index.html | 0001104659-26-056296 |
| Document: 0001104659-26-056296.txt | 0001104659-26-056296 |
Track record
23 reports on ARGX
7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
- Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
- Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers